Recent breakthroughs in immunotherapy feature Regeneron's bispecific antibody Lynozyfic approved for relapsed and refractory multiple myeloma, offering improved dosing flexibility compared to existing treatments. Meanwhile, a multidisciplinary team at Milan’s SR-TIGET has engineered enhanced CAR-T cellular communication strategies to improve efficacy against glioblastoma, historically resistant to immunotherapies. Additionally, new findings describe the role of mast cells in augmenting MAIT cell anti-tumor responses, and innovative approaches to enhance CAR-T cell penetration into solid tumors are under exploration, promising transformative changes in oncologic treatment.